CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) and Veracyte (NASDAQ:VCYT – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Profitability
This table compares CAMP4 Therapeutics and Veracyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CAMP4 Therapeutics | -2,543.74% | -252.79% | -85.65% |
| Veracyte | 20.37% | 9.26% | 8.61% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for CAMP4 Therapeutics and Veracyte, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CAMP4 Therapeutics | 1 | 1 | 7 | 0 | 2.67 |
| Veracyte | 1 | 2 | 6 | 2 | 2.82 |
Risk & Volatility
CAMP4 Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Earnings & Valuation
This table compares CAMP4 Therapeutics and Veracyte”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CAMP4 Therapeutics | $3.50 million | 77.45 | -$80.40 million | ($2.32) | -1.86 |
| Veracyte | $517.15 million | 6.45 | $66.35 million | $1.41 | 29.41 |
Veracyte has higher revenue and earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Summary
Veracyte beats CAMP4 Therapeutics on 10 of the 13 factors compared between the two stocks.
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
